Tsumura & Co. engages in the production and sale of Kampo extract intermediates and granular Kampo formulations in Japan and internationally. The company offers products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation and hemorrhoids, as well as body aches, children's sickness, stress, urinary problems, and cold, cough, and nasal/throat inflammation symptoms. It is also involved in manufacturing and sales of prescription drugs and over-the-counter Kampo medicines. In addition, it produces and sells alcoholic beverages and food products. Tsumura & Co. was founded in 1893 and is headquartered in Tokyo, Japan.
Research context
Tsumura & Co appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Tsumura & Co is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.
From a valuation standpoint, the stock is 96.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.4.
Tsumura & Co's total revenue rose by 3.2% to $35B since the same quarter in the previous year.
Its net income has increased by 13.3% to $5B since the same quarter in the previous year.
Finally, its free cash flow grew by 59.3% to $-245M since the same quarter in the previous year.
Based on the above factors, Tsumura & Co gets an overall score of 4/5.